-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IXC-103 in Friedreich Ataxia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IXC-103 in Friedreich AtaxiaDrug Details:IXC-103 (dimethyl fumarate) is under development for the treatment of mitochondrial myopathy,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ETH-155008 in Relapsed Chronic Lymphocytic Leukemia (CLL)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ETH-155008 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug Details:ETH-155008 is under development for the treatment of...
-
Product Insights
![]()
Friedreich Ataxia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Friedreich Ataxia Clinical Trials Market Report Overview The Friedreich Ataxia clinical trial market research report provides an overview of the Friedreich Ataxia clinical trials scenario. The report provides top-line data relating to the clinical trials on Friedreich Ataxia. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – IXC-103
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry IXC-103 Drug Details IXC-103 (dimethyl fumarate) is under development for the treatment of mitochondrial...
-
Product Insights
![]()
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Leber’s hereditary optic neuropathy (LHON) symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer-treating drugs, stress-related chemicals, some antibiotics, and cyanogens. The LHON pipeline drugs market research report provides an analysis of the LHON drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history,...
-
Product Insights
![]()
Friedreich Ataxia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Friedreich Ataxia Drugs in Development Report Overview Friedreich’s ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Its signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties, and diabetes. The Friedreich Ataxia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Friedreich Ataxia, complete with analysis...
-
Product Insights
![]()
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. The Nuclear Factor Erythroid 2 Related Factor 2 - Drugs...
-
Product Insights
![]()
Duchenne Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Duchenne Muscular Dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Duchenne Muscular Dystrophy and...
-
Product Insights
![]()
Friedreich Ataxia Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Friedreich Ataxia Global Clinical Trials Review, H2, 2017" provides an overview of Friedreich Ataxia clinical trials scenario. This report provides top line data relating to the clinical trials on Friedreich Ataxia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
![]()
Retinal Degeneration Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Retinal Degeneration Global Clinical Trials Review, H2, 2018" provides an overview of Retinal Degeneration clinical trials scenario. This report provides top line data relating to the clinical trials on Retinal Degeneration. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.